Category: Antibodies

Active filters

  • Categories: Antibody panels
  • Categories: Control Antibodies
  • Categories: Intracellular Functional Antibodies
Reference: HY-P99315

Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research.

Reference: HY-P9947

Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.

Reference: HY-P99902

Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1.

Reference: HY-P99417

Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma.

Reference: HY-P99715

Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers.

Reference: ARG30277

The mosquito-borne Zika virus (ZIKV) is prompting worldwide concern due to its connection to neurological disorders including microcephaly. Zika virus belongs to the flavivirus family which encompasses Dengue, yellow fever, West Nile and more different viruses. The connection of neurological disorders creates a need for further research into the ZIKV infection and therapeutic approaches. For more ZIKA virus antibody and ZIKA virus antibody Duo products, please refer to Choose the Best ZIKA Virus Antibodies

Reference: HY-P99794

Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects.